Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Trevi Therapeutics (TRVI) and increased its price target from $25 to $30. This indicates a continued positive outlook from the analyst, suggesting potential upside for the stock.
Cantor Fitzgerald analyst Josh Schimmer has maintained an 'Overweight' rating on Trevi Therapeutics (TRVI) and raised the price target from $25 to $30. This action signals continued confidence in the company's prospects and suggests that the analyst believes the stock has further room to grow. For traders, this could be seen as a positive signal, potentially leading to increased buying interest in the short term. The long-term implication is that if other analysts follow suit or if the company's fundamentals align with this optimistic view, the stock could see sustained upward momentum. A key opportunity for traders is to consider this analyst upgrade as a potential catalyst for a price movement.